After five years of being bashed on unsafe, ineffective, uncontrollable spike protein-producing (Spikevax, mNEXSPIKE) vaccines, Moderna is solidly back home in the cancer business, and their stock performance couldn’t be any better.
The mRNA Cancer Long Game: Moderna’s Pivot from Pandemic to Personalised Chemotherapy
There’s a narrative that’s taken hold in the financial press and biotechnology cheerleading circles: Moderna, having saved humanity from covid, is now developing “cancer vaccines” that will do for oncology what Operation Warp Speed did for respiratory viruses.
This is marketing, not medicine.
What Moderna is actually doing is using synthetic messenger RNA as a delivery mechanism for personalised neoantigens as a part of toxic combination chemotherapy. Calling these “vaccines” is a linguistic sleight of hand designed to borrow the halo from childhood immunisation while obscuring the reality of what’s being injected into patients’ bodies week after week.
The remainder of this article is behind a paywall. Click HERE to subscribe to Focal Points and read the full article. After subscribing, you can claim one free-to-read article.
[Note from The Exposé: A cancer “vaccine” programme is also underway in the UK, with clinical trials currently taking place. “The NHS Cancer Vaccine Launch Pad (CVLP) is a platform that will speed up access to messenger ribonucleic acid (mRNA) personalised cancer vaccine and other immunotherapy clinical trials for people who have been diagnosed with cancer. It will also accelerate the development of cancer vaccines and other immunotherapies as a form of cancer treatment,” NHS England says.]
Hellbound and Down 